Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results

e revised 2008 financial guidance the Company is estimating a lower loss from operations in the range from $14.4 million to $15.4 million. The Company expects annual weighted average shares outstanding for 2008 will be approximately 57.7 million common shares.

Recent Corporate Events:

August 2008: The Company announced that the FDA granted orphan drug designation for our lead drug candidate, MP-470, for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer. The FDA accepted the Company's application upon review of data from in vitro studies in glioblastoma cell lines that demonstrated that either MP-470 or ionizing radiation (IR) alone induce cell death, but when used in combination they synergistically increase cell death by more than two-fold over either agent alone. MP-470 is currently being evaluated in Phase 1 trials as a single agent and in combination with chemotherapy in patients with solid tumors. A Phase 1b study in patients with GBM is planned.

October 2008: The Company presented five posters at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" on October 23 and 24, 2008. The poster presentations reviewed clinical and non-clinical advances in MP-470, SGI-1252 and SGI-1776. Poster presentations included the following abstracts:
-- Abstract 403: Clinical responses in highly refractory solid tumor

patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor,

in combination with standard of care chemotherapy regimens: preliminary

report from a multi-institutional Phase-1b clinical trial.

-- Abstract 332: In vivo activity of SGI-1776, an orally active PIM

kinase inhibitor.

-- Abstract 426: Effects of food on the single-dose pharmacokinetics of

oral MP-470 capsules.

-- Abstract 480: MP-470, a novel multi-targeted tyrosine kinase inhibitor

targeting Rad51 is not toxic to human primary ma

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
(Date:9/17/2014)... MA (PRWEB) September 17, 2014 ... Safety (ACRES) , a multi-stakeholder non-profit collaborative building ... efficiency in clinical research, today announced Phase 3 ... , Amir H. Kalali, Vice-President, ... and Arti Bajpai, President, Compliance and Quality Integration ...
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014 This ... by the following Product Segments: Software, Hardware, and Biocontent. The ... Canada , Japan , ... Latin America , and Rest of World. Annual estimates ... Also, a seven-year historic analysis is provided for these markets. ...
(Date:9/16/2014)... , Sept. 16, 2014  Biocom, the association representing ... community, recognizes the 9 th Annual National Health ... of IT technologies in improving our health care system. ... is one of the world,s most vibrant hubs for ... mobile health applications to genomic testing to remote patient ...
(Date:9/16/2014)... COLUMBIA, Mo. From cell phones to cars ... everyday life. Scientists and technology companies constantly are ... Now, for the first time using a water-based ... created a long-lasting and more efficient nuclear battery ... as a reliable energy source in automobiles and ...
Breaking Biology Technology:Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Biocom Recognizes National Health IT Week 2
... CHERRY HILL, N.J., Sept. 21 Nuvilex, Inc. (OTC Bulletin ... venture partner with Reme-Flu(TM), will be incorporating Syn-X9(TM) proprietary delivery ... remedy designed to help prevent and treat flu-type symptoms resulting ... , , The unique attributes ...
... Merrimack Pharmaceuticals, Inc., announced today that Clet Niyikiza, Ph.D., ... Niyikiza comes to Merrimack from GlaxoSmithKline (GSK) where he was ... Niyikiza has extensive drug development experience with a career ... which he has led ten New Drug Application teams that ...
... , , ROCKVILLE, Md., Sept. 21 ... the U.S. Food and Drug Administration (FDA) has approved its Investigational New ... Lateral Sclerosis (ALS or Lou Gehrig,s disease) with its spinal cord stem ... ) , , Neuralstem is the first ...
Cached Biology Technology:Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 2Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 3Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 3Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 4
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... a 10-km diameter chunk of rock hit the Yukatan peninsula ... the force of 100 teratons of TNT. It left a ... wildfires, global earthquakes and volcanism are widely accepted to have ... of the mammals. But what happened to the plants on ... researchers from the University of Arizona reveals that the meteorite ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... a sudden halt, the carbon dioxide already in Earth,s atmosphere ... according to Princeton University-led research published in the journal ... take a lot less carbon than previously thought to reach ... an Earth on which, after 1,800 billion tons of carbon ...
... Think Greenland,s ice sheet is small today? It was ... history from 3-5,000 years ago, according to scientists who studied ... interpreting the Arctic fossil record. "What,s really interesting about this ... 5,000 years ago, maybe as late as 4,000 years ago. The ...
... Gregg, an assistant professor of mechanical engineering and bioengineering ... Computer Science this fall, is a recipient of a ... for research that will combine robot control theory and ... orthotic devices. "According to the American Society of ...
Cached Biology News:Even if emissions stop, carbon dioxide could warm Earth for centuries 2Even if emissions stop, carbon dioxide could warm Earth for centuries 3Greenland's shrunken ice sheet: We've been here before 2Greenland's shrunken ice sheet: We've been here before 3UT Dallas professor wins $2.3 million NIH award 2UT Dallas professor wins $2.3 million NIH award 3
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... be used for the identification of potential biomarkers ... and other diseases. Due to the fact that ... it provides an attractive alternative to blood plasma ... ProteoSpin Urine Protein Concentration Micro Kit provides ...
... forces with the Mickle Laboratory Engineering Company ... This tissue sectioning system has been designed ... experiments and to be especially applicable to ... or from small organs. Its special features ...
Biology Products: